KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Cash (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Change in Cash data on record, last reported at $33.9 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 136.66% year-over-year to $33.9 million; the TTM value through Dec 2025 reached $130.2 million, up 182.82%, while the annual FY2025 figure was $130.2 million, 182.82% up from the prior year.
  • Change in Cash reached $33.9 million in Q4 2025 per IONS's latest filing, down from $41.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $236.2 million in Q4 2021 and bottomed at -$326.7 million in Q1 2022.
  • Average Change in Cash over 5 years is -$1.3 million, with a median of $27.3 million recorded in 2023.
  • Peak YoY movement for Change in Cash: tumbled 2080.95% in 2022, then skyrocketed 662.05% in 2023.
  • A 5-year view of Change in Cash shows it stood at $236.2 million in 2021, then plummeted by 116.31% to -$38.5 million in 2022, then skyrocketed by 222.55% to $47.2 million in 2023, then tumbled by 296.01% to -$92.5 million in 2024, then surged by 136.66% to $33.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $33.9 million in Q4 2025, $41.0 million in Q3 2025, and $33.1 million in Q2 2025.